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Abstract
Background: The ankle-brachial index (ABI) is an indicator of peripheral arterial damage and a low (ABI ≤ 1.0) or
borderline (ABI = 1.00–1.09) value is associated with risk of cardiovascular disease events. A low ratio of serum
eicosapentaenoic acid to arachidonic acid (EPA/AA) is also a risk factor for cardiovascular disease events. This study
examined associations between the ABI and the EPA/AA ratio in smokers and non-smokers with type 2 diabetes
mellitus (T2DM).
Findings: Blood data including EPA, AA, and ABI were measured in smokers and non-smokers with T2DM enrolled at
Jichi Medical University (n = 116, male 86 %, mean age 59 yr). The patients were classified into two groups according to
their ABI level: <1.1 (low to borderline) or ≥1.1 (high). The EPA/AA ratio in smoking patients with ABI < 1.1 (n = 26; EPA/
AA = 0.25) was significantly lower than in those with ABI≥ 1.1 (n = 32; EPA/AA = 0.34; p = 0.03), but was not significantly
different in non-smoking patients. The EPA/AA ratio was independently, significantly, and positively correlated with the
ABI level (β= 0.41; p < 0.01) after adjusting for multiple variables only in smoking patients with T2DM.
Conclusions: The EPA/AA ratio may be associated with subclinical peripheral arterial damage in smokers with T2DM.
Further studies are warranted.
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Findings
Background
Smokers have an increased risk of peripheral arterial dam-
age, which is associated with cardiovascular disease (CVD)
events in patients with diabetes mellitus (DM) [1]. Multi-
faceted studies of subclinical peripheral arterial damage are
thus important for prevention of CVD in patients with
DM. Assessment of peripheral arterial damage is often con-
ducted noninvasively using the ankle-brachial index (ABI)
[2, 3]. Although ABI < 0.9 has diagnostic value for periph-
eral arterial disease (PAD) [2, 3], a low-to-borderline level
of ABI (0.9–1.1) is also associated with increased risk of
CVD events and related mortality [4, 5].
A low ratio of serum eicosapentaenoic acid to arachi-
donic acid (EPA/AA) has also been correlated with CVD
events in patients with DM [6, 7]. An additional study
reported that the EPA/AA ratio was positively associated
with the ABI level in hospitalized patients, although it
did not take into account smoking habits or DM path-
ology [8]. Recently, we reported that a low EPA/AA ratio
is often seen in elderly patients with type 2 DM
(T2DM), particularly in smokers [9]. However, the asso-
ciation between the ABI and EPA/AA ratio has not been
elucidated; therefore, in the present study, we aimed to
investigate the correlation between ABI and EPA/AA
among smokers with T2DM.
Subjects and methods
Study participants
A cross-sectional study of 116 smoking and non-smoking
T2DM patients (2 groups of 50 men and 8 women, mean
age 59 yr in each group) who visited the Jichi Medical
University Hospital, Shimotsuke, Japan for more 1 yr was
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conducted from April to September 2014. Smoking habits
were confirmed via self-reports. Current smoking status
was designated as either smoking or not smoking. None
of the patients were taking medications containing EPA or
AA. We excluded patients with a history of CVD events,
recent acute illness, systemic inflammatory disease, severe
nephropathy (i.e., stage 3–5), liver dysfunction, type 1
DM, and PAD. The study was approved by the Jichi
Medical University Ethical Committee and informed con-
sent was obtained from all patients.
Hypertension was defined as systolic blood pressure
(SBP) ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg,
and/or anti-hypertensive drug use [10]. Nephropathy was
defined as a urinary albumin-to-creatinine ratio > 30 mg/g
creatinine, above the micro albuminuria level [11].
Data collection
Fasting blood samples were collected at the outpatient
clinic to measure levels of glucose, hemoglobin A1c
(HbA1c), total cholesterol, triglycerides, high-density lipo-
protein cholesterol, EPA, and AA. A high-performance li-
quid chromatography system (HLA-723G8; Tosoh Corp.,
Tokyo, Japan) was used to measure HbA1c. Serum lipids
were extracted by Folch’s method and the fatty acids (in-
ternal standard, tricosanoic acid [C23:0]) were methylated
with boron trifluoride and methanol. EPA and AA levels
in the methylated fatty acids were then analyzed by gas
chromatography (GC-2010; Shimadzu Corp., Kyoto,
Japan) with a capillary column (TC-70; GL Sciences Inc.,
Tokyo, Japan).
The ABI was determined using a pulse pressure analyzer
(model BP-203RPEIII; Omron Colin Corp., Tokyo, Japan)
as previously described [12]. ABI was determined based
on the SBP in both the upper (brachial arterial) and lower
(tibial arterial) arteries [13] and was calculated by dividing
the ankle SBP by the brachial SBP. The patient population
was divided into two ABI groups (<1.1 and ≥1.1) based on
previous studies [4, 14].
Statistical analysis
Smoking and non-smoking patients were matched for
age and sex. Comparisons between smoking and non-
smoking groups were conducted using an unpaired t-test
or chi-square test. Differences in parameters between
ABI groups were analyzed using an unpaired t-test or
chi-square test. Correlations between absolute ABI and
the other parameters (including the EPA/AA ratio) were
examined using a Pearson’s correlation test and stepwise
multiple regression analysis (SPSS software; SPSS Inc.,
IL, USA). All parameters were included in the stepwise
multiple regression model except for the EPA, which
was not included due to multicollinearity with the EPA/
AA ratio and the stronger correlation of the EPA/AA
ratio with the ABI. Parameters with skewed distributions
were log-transformed prior to all analyses. A p-value of
<0.05 was considered to be significant.
Results
Clinical characteristics of the study population for the
smoking and non-smoking groups are shown in Table 1.
The HbA1c level and percentage with neuropathy com-
plications were higher in the smoking group than in the
non-smoking group.
Two patients with ABI < 0.9 (the defined PAD level)
were included in the smoking group. In the smoking
group, patients with ABI < 1.1 had significantly lower
EPA/AA ratios than did those with ABI ≥ 1.1, while the
AA and EPA alone did not show clear differences between
patients with ABI < 1.1 and ≥ 1.1. The other parameters
were not statistically different between the groups
(Table 2). In contrast, patients with ABI ≤ 1.1 had a signifi-
cantly higher HbA1c than did those with ABI ≥ 1.1 in the
Table 1 Clinical characteristics of the study population by
current smoking habit
Parameter Non-smoker (n = 58) Smoker (n = 58) p
Age, yr 59 ± 12 59 ± 10 0.91
Sex, male (%) 50 (86 %) 50 (86 %) 1.00
Body mass index,
kg/m2
26.3 ± 4.4 26.2 ± 4.5 0.88
Systolic blood pressure,
mm Hg
131 ± 14 131 ± 11 0.80
Diastolic blood pressure,
mm Hg
77 ± 11 79 ± 10 0.43
Antihypertensive drugs,
n (%)
33 (57 %) 43 (74 %) 0.05
Glucose, mg/dL 149 ± 62 139 ± 42 0.29
Hemoglobin A1c, % 7.2 ± 1.0 7.6 ± 1.0 0.045*
Insulin injection, n (%) 15 (26 %) 14 (24 %) 0.83
Retinopathy, n (%) 18 (31 %) 23 (40 %) 0.33
Neuropathy, n (%) 24 (41 %) 36 (62 %) 0.03*
Nephropathy, n (%) 19 (33 %) 25 (43 %) 0.25
LDL cholesterol,
mg/dL
97 ± 31 95 ± 33 0.73
HDL cholesterol,
mg/dL
60 ± 17 55 ± 16 0.13
Triglycerides, mg/dL 114 (73–160) 125 (91–173) 0.19
Statin drugs, n (%) 21 (36 %) 22 (38 %) 0.85
AA, μg/mL 173 (151–212) 181 (152–234) 0.49
EPA, μg/mL 60 (41–96) 52 (36–86) 0.28
EPA/AA ratio 0.37 (0.23–0.56) 0.29 (0.19–0.42) 0.08
Ankle-brachial index 1.14 ± 0.07 1.11 ± 0.09 0.07
Data are means ± standard deviations, medians (interquartile ranges), or
numbers (%)
LDL low-density lipoprotein, HDL high-density lipoprotein, AA arachidonic acid,
EPA eicosapentaenoic acid
* p < 0.05 for comparison between groups by smoking (t-test or
chi-square test)
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non-smoking group. There were no statistical differences
in the other parameters, including EPA/AA, with ABI
levels in the non-smoking group.
Correlations of absolute ABI with the other parame-
ters are listed in Table 3. Pearson’s correlation tests
found that EPA and the EPA/AA ratio were significantly
and positively correlated with ABI levels in the smoking
group, while HbA1c was significantly and negatively cor-
related with ABI levels in the non-smoking group. Step-
wise multiple regression analysis revealed that the EPA/
AA ratio was independently, significantly, and positively
correlated with ABI levels and that use of statin drugs
was inversely correlated with ABI levels in the smoking
group, while HbA1c was independently, significantly,
and negatively correlated with ABI levels in the non-
smoking group.
Discussion
We found that the EPA/AA ratio was lower in patients
with ABI < 1.1 than in those with ABI ≥ 1.1, with a positive
correlation between the EPA/AA ratio and ABI in
smokers with T2DM. To our knowledge, a relationship
between the EPA/AA ratio and ABI level among smokers
or non-smokers with T2DM has not previously been re-
ported. Accordingly, the results of this study suggest that
the EPA/AA ratio may be associated with subclinical PAD
in smokers with T2DM.
By contrast of n-3 fatty acids, particularly EPA, n-6 fatty
acids, particularly AA, impair peripheral arteries by creating
vasoactive oxygen radicals and promoting cyclooxygenase
metabolism [15, 16]. In smokers, a delayed conversion of
AA to eicosanoids is known [17–19], this may result in
endothelial dysfunction in peripheral arteries [20]. This is a
possible mechanism for a positive correlation between the
EPA/AA ratio and ABI levels in smokers with DM, al-
though this requires further research.
Based on the results of our stepwise regression model,
ABI was inversely associated with the use of statin drugs
in the smoking group. Statins are often prescribed for
patients with DM, particularly when the patients may
have complications of DM. As a result, patients with
subclinical PAD may use statins. This is only a hypoth-
esis; however, similar results were reported in a previous
study [21].
Table 2 Clinical characteristics of the study population by ABI (<1.1 and ≥ 1.1)
Non-smoker p Smoker p
Parameter ABI < 1.1 (n = 17) ABI ≥ 1.1 (n = 41) ABI < 1.1 (n = 26) ABI ≥ 1.1 (n = 32)
Age, yr 56 ± 14 60 ± 11 0.21 58 ± 10 60 ± 11 0.61
Sex, male (%) 15 (88 %) 35 (85 %) 0.77 22 (85 %) 28 (88 %) 0.75
Body mass index, kg/m2 26.5 ± 5.6 26.2 ± 3.9 0.77 25.5 ± 3.8 26.7 ± 5.0 0.31
Systolic blood pressure,
mm Hg
133 ± 17 130 ± 13 0.45 131 ± 10 132 ± 12 0.77
Diastolic blood pressure,
mm Hg
80 ± 13 76 ± 10 0.22 79 ± 9 78 ± 10 0.76
Antihypertensive drugs, n (%) 12 (71 %) 21 (51 %) 0.18 20 (77 %) 23 (72 %) 0.66
Glucose, mg/dL 157 ± 39 146 ± 70 0.55 137 ± 42 140 ± 43 0.74
Hemoglobin A1c, % 7.7 ± 1.2 7.0 ± 0.8 0.01* 7.6 ± 1.0 7.5 ± 1.0 0.82
Insulin injection, n (%) 7 (41 %) 8 (20 %) 0.09 3 (12 %) 11 (34 %) 0.06
Retinopathy, n (%) 6 (35 %) 12 (29 %) 0.65 9 (35 %) 14 (44 %) 0.48
Neuropathy, n (%) 10 (59 %) 14 (34 %) 0.08 10 (38 %) 15 (47 %) 0.52
Nephropathy, n (%) 5 (29 %) 14 (34 %) 0.73 16 (62 %) 20 (63 %) 0.94
LDL cholesterol, mg/dL 96 ± 38 97 ± 28 0.88 95 ± 39 94 ± 28 0.95
HDL cholesterol, mg/dL 61 ± 18 59 ± 16 0.68 52 ± 14 57 ± 18 0.23
Triglycerides, mg/dL 127 (79–217) 107 (69–144) 0.18 139 (116–233) 118 (83–159) 0.09
Statin drugs, n (%) 6 (35 %) 15 (37 %) 0.93 13 (50 %) 9 (28 %) 0.09
AA, μg/mL 176 (144–214) 173 (150–210) 0.51 191 (158–244) 180 (134–227) 0.18
EPA, μg/mL 64 (46–114) 60 (41–97) 0.26 49 (33–69) 68 (41–96) 0.07
EPA/AA ratio 0.44 (0.21–0.75) 0.37 (0.23–0.55) 0.56 0.25 (0.16–0.40) 0.34 (0.20–0.69) 0.03*
Ankle-brachial index 1.06 ± 0.04 1.17 ± 0.05 <0.01** 1.03 ± 0.06 1.18 ± 0.05 <0.01**
Data are means ± standard deviations, medians (interquartile ranges), or numbers (%)
LDL low-density lipoprotein, HDL high-density lipoprotein, AA arachidonic acid, EPA eicosapentaenoic acid
* p < 0.05, ** p < 0.01 for comparison between ABI groups (t-test or chi-square test)
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The present study had certain limitations. It was a
cross-sectional study with a small sample size; thus, fur-
ther intervention and a placebo control study are needed.
Additionally, as there was no information regarding diet-
ary fish consumption, smoking dose, or smoking duration
(e.g., the Brinkman index), and because the cigarette type
was not investigated in detail, these factors could not be
considered in our analysis.
Conclusions
In summary, the EPA/AA ratio may be associated with
subclinical PAD in smokers with T2DM. The utility of
measuring the EPA/AA ratio along with ABI should be
further investigated in future studies.
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